yes, I'm talking about successful phase 1 trial. Its good enough to take this to $5B mkt cap. Because , bio-tech trial is part of business but not 100% focused on that. There are other revenue sources in the mean time. They will have to raise some money but not as much as other bio tech companies.
Market Data 
Markets 
AI
